Market Cap
US$10.0b
Last Updated
2020/06/06 02:48 UTC
Data Sources
Company Financials +
Executive Summary
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Moderate growth potential and overvalued.
Similar Companies
Share Price & News
How has QIAGEN's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: QGEN has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.09%
QGEN
1.0%
US Life Sciences
3.8%
US Market
1 Year Return
12.6%
QGEN
19.8%
US Life Sciences
9.7%
US Market
Return vs Industry: QGEN underperformed the US Life Sciences industry which returned 19.6% over the past year.
Return vs Market: QGEN exceeded the US Market which returned 8.9% over the past year.
Shareholder returns
| QGEN | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.09% | 1.0% | 3.8% |
| 30 Day | 3.1% | 9.0% | 11.4% |
| 90 Day | 5.4% | 16.4% | 6.8% |
| 1 Year | 12.6%12.6% | 20.1%19.8% | 12.1%9.7% |
| 3 Year | 28.8%28.8% | 85.4%84.1% | 36.2%27.2% |
| 5 Year | 76.3%69.6% | 131.7%128.8% | 63.7%45.4% |
Price Volatility Vs. Market
How volatile is QIAGEN's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall St
Update: QIAGEN (NYSE:QGEN) Stock Gained 43% In The Last Five Years4 months ago | Simply Wall St
What Kind Of Investor Owns Most Of QIAGEN N.V. (NYSE:QGEN)?4 months ago | Simply Wall St
We Think QIAGEN (NYSE:QGEN) Is Taking Some Risk With Its DebtValuation
Is QIAGEN undervalued compared to its fair value and its price relative to the market?
4.01x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: QGEN ($43.83) is trading above our estimate of fair value ($28.11)
Significantly Below Fair Value: QGEN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: QGEN is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.
PE vs Market: QGEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate QGEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: QGEN is good value based on its PB Ratio (4x) compared to the US Life Sciences industry average (5.9x).
Next Steps
Future Growth
How is QIAGEN forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
22.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: QGEN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).
Earnings vs Market: QGEN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: QGEN's is expected to become profitable in the next 3 years.
Revenue vs Market: QGEN's revenue (5% per year) is forecast to grow slower than the US market (8.8% per year).
High Growth Revenue: QGEN's revenue (5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: QGEN's Return on Equity is forecast to be low in 3 years time (12%).
Next Steps
Past Performance
How has QIAGEN performed over the past 5 years?
-15.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: QGEN is currently unprofitable.
Growing Profit Margin: QGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: QGEN is unprofitable, and losses have increased over the past 5 years at a rate of -15% per year.
Accelerating Growth: Unable to compare QGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QGEN is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (10.6%).
Return on Equity
High ROE: QGEN has a negative Return on Equity (-1.25%), as it is currently unprofitable.
Next Steps
Financial Health
How is QIAGEN's financial position?
Financial Position Analysis
Short Term Liabilities: QGEN's short term assets ($1.6B) exceed its short term liabilities ($997.2M).
Long Term Liabilities: QGEN's short term assets ($1.6B) do not cover its long term liabilities ($1.7B).
Debt to Equity History and Analysis
Debt Level: QGEN's debt to equity ratio (66.4%) is considered high.
Reducing Debt: QGEN's debt to equity ratio has increased from 42.1% to 66.4% over the past 5 years.
Debt Coverage: QGEN's debt is not well covered by operating cash flow (18.3%).
Interest Coverage: QGEN is unprofitable, therefore interest payments are not well covered by earnings.
Balance Sheet
Next Steps
Dividend
What is QIAGEN's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate QGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate QGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if QGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if QGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of QGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.4yrs
Average management tenure
CEO
Thierry Bernard (54yo)
0.67
Tenure
US$1,208,000
Compensation
Mr. Thierry Bernard has been Chief Executive Officer of QIAGEN N.V. since March 2020 and had been its Interim Chief Executive Officer since October 2019 until March 2020. He has been a Senior Vice Presiden ...
CEO Compensation Analysis
Compensation vs Market: Thierry's total compensation ($USD1.21M) is below average for companies of similar size in the US market ($USD11.52M).
Compensation vs Earnings: Insufficient data to compare Thierry's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 0.67yr | US$1.21m | 0.021% $2.1m | |
| CFO, MD & Member of Management Board | 16.42yrs | US$925.00k | 0.071% $7.1m | |
| Senior Advisor | 0.67yr | US$7.55m | no data | |
| Senior VP & Head of Global Operations | 1.5yrs | no data | no data | |
| Vice President of Corporate Communications & Investor Relations | 9.67yrs | no data | no data | |
| Head of Corporate Business Development | 5.08yrs | no data | no data | |
| SVP & Head of Human Resources | 0.67yr | no data | no data | |
| Senior Vice President of Life Science Business Area | 2.42yrs | no data | no data | |
| Senior Vice President of Qiagen Digital Insights Business Area | 2.42yrs | no data | no data | |
| Vice President of Global Treasury | no data | no data | no data |
2.4yrs
Average Tenure
53.5yo
Average Age
Experienced Management: QGEN's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Supervisory Director | 16.42yrs | US$75.50k | 1.56% $155.9m | |
| Independent Supervisory Director | 9yrs | US$96.50k | 0.013% $1.3m | |
| Independent Supervisory Board Chairman | 2yrs | US$173.00k | no data | |
| Independent Supervisory Director | 7yrs | US$82.50k | no data | |
| Independent Supervisory Director | 6yrs | US$63.50k | 0.0026% $261.2k | |
| Independent Supervisory Director | 7yrs | US$89.50k | 0.0070% $697.6k | |
| Independent Supervisory Director | 4.42yrs | US$63.50k | 0.00094% $94.1k |
7.0yrs
Average Tenure
62yo
Average Age
Experienced Board: QGEN's board of directors are considered experienced (7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: QGEN insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
QIAGEN N.V.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: QIAGEN N.V.
- Ticker: QGEN
- Exchange: NYSE
- Founded: 1986
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$10.009b
- Shares outstanding: 228.37m
- Website: https://www.qiagen.com
Number of Employees
Location
- QIAGEN N.V.
- Hulsterweg 82
- Venlo
- Limburg
- 5912 PL
- Netherlands
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| QGEN | NYSE (New York Stock Exchange) | Yes | Common Shares | US | USD | Jun 1996 |
| QIA | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jun 1996 |
| QIA | XTRA (XETRA Trading Platform) | Yes | Common Shares | DE | EUR | Jun 1996 |
| 0RLT | LSE (London Stock Exchange) | Yes | Common Shares | GB | EUR | Jun 1996 |
| QIAD | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Common Shares | GB | EUR | Jun 1996 |
| QGEN | SWX (SIX Swiss Exchange) | Yes | Common Shares | CH | CHF | Jun 1996 |
| QGEN | WBAG (Wiener Boerse AG) | Yes | Common Shares | AT | EUR | Jun 1996 |
| QIA | ETLX (Eurotlx) | Yes | Common Shares | IT | EUR | Jun 1996 |
| QIAB | DB (Deutsche Boerse AG) | NPV | DE | EUR | May 2020 |
Biography
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits designed for primary sample materials (deoxyribonucleic acid, ribonucleic acid, and proteins), manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and buffers; secondary sample technology consumables, including kits and components for purification of nucleic acids and proteins from secondary sample materials, and molecular biology reagents; and instruments for nucleic acid purification and accessories. It also provides assay content consumables, such as kits, assays, reagents, and controls for identification and analysis of sequence-specific targets, such as DNA, methylated DNA, bacterial DNA, RNA, and miRNA with various technologies, such as PCR, pyrosequencing, and hybridization in assay and array format, as well as oligonucleotide synthesis, siRNAs, and bisulfite conversion; custom-developed and configured enzymes and products; assay foundation consumables; modular PCR system, one-step molecular analysis of hard-to-diagnose syndromes, fully integrated medium to high throughput PCR test analysis, and specialized instruments; and custom laboratory and genomic services. In addition, the company offers predefined and custom next-generation sequencing gene panels (DNA and RNA), library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and human ID/forensics sample collection consumables and human ID/forensics sample collection consumables. It serves molecular diagnostics, applied testing, pharma, and academia customers. The company has collaboration agreements with Amgen Inc., CLIA-certified laboratories, and NuProbe Global. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/06 02:48 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.